品牌仿製药市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类别、按应用、配销通路、地区、竞争细分

2022 年全球品牌仿製药市场估值达到 2300.2 亿美元，预计在预测期内将出现显着增长，预计到 2028 年复合年增长率 (CAGR) 为 6.25%，2028 年将达到 3332 亿美元。2028 年。品牌仿製药（即以不同品牌名称重新发布的药品）的采用率有所增加。这些药物以较低的成本重新推出，虽然形状、大小、颜色和味道可能有所不同，但药物的核心保持不变。当药物专利到期时就会发生这种情况。品牌仿製药包括用于治疗高血压、糖尿病、背痛、甲状腺问题和关节炎等各种疾病的药物。他们提供具有成本效益的替代方案，以保持市场竞争力，同时保持相同水准的品质和治疗效果。

主要市场驱动因素

• 1.专利到期时间增加：随着品牌药的专利到期，仿製药製造商获得了以其版本进入市场的合法权利。这种竞争往往会导致药品价格下降，使消费者更能负担医疗保健费用。此外，它使人们能够更广泛地获得基本药物，特别是在成本成为障碍的地区，从而扩大了市场。品牌仿製药的价格通常低于品牌仿製药，这可以为医疗保健系统节省大量成本，特别是在医疗保健预算有限的发展中国家或地区。政府和医疗保健提供者可能更愿意开处方和购买品牌仿製药，进一步推动市场成长。专利到期后，多家仿製药製造商进入市场会加剧竞争。这种竞争可以推动配方、输送方法和包装方面的创新，因为製造商努力使他们的产品与众不同，以获得更大的市场份额。在某些情况下，专利到期后推出多种仿製药可能会导致市场饱和。因此，由于激烈的竞争，仿製药价格可能会大幅下降，这限制了仿製药製造商的收入潜力，但有利于消费者和医疗保健系统。仿製药市场竞争的加剧可以激励製造商投资于研发，以提高仿製药产品的品质、功效和安全性。这种对创新的关注可以进一步推动品牌仿製药市场的成长。

市场概况
预测期	2024-2028
2022 年市场规模	2300.2亿美元
2028 年市场规模	3332亿美元
2023-2028 年复合年增长率	6.25%
成长最快的细分市场	网路药局
最大的市场	北美洲

• 2.医生和患者的接受度不断提高：医生对品牌仿製药的认可在其市场成长中发挥关键作用。当医生对品牌仿製药的品质和有效性有信心时，他们更倾向于向患者开药。医生的建议和对品牌仿製药疗效的信任可以减轻患者对从品牌药物转向仿製药的担忧。医生在开药时通常会考虑患者的经济负担。如果医生认为品牌仿製药具有与品牌药类似的治疗效果，他们可能更有可能开立处方药来帮助患者节省医疗费用。製药公司和医疗机构可以帮助医生了解品牌仿製药与品牌药物的品质、安全性和等效性。适当的教育可以积极影响医生的接受度和处方习惯。患者可能会对从知名品牌药物过渡到仿製药感到犹豫。品牌仿製药的正面体验和成功治疗结果可以增强患者对其有效性的信心，从而提高接受度。患者通常相信医生的建议。如果医生解释品牌仿製药的优势，包括其价格实惠和同等的治疗效果，患者就更有可能接受它们。成本考虑大大提高了患者的接受度。无力负担昂贵品牌药物的患者可能更愿意使用品牌仿製药，只要他们能保证其安全性和有效性。
• 3.慢性病发生率上升：全球慢性病发生率不断上升，导致对治疗这些疾病的药物的需求不断增长。品牌仿製药为品牌药提供了具有成本效益的替代品，使更多需要持续治疗的患者更容易获得它们。慢性病通常需要长期的药物治疗，这可能会对患者造成经济负担。品牌仿製药比品牌仿製药更实惠，对于希望在不增加财务压力的情况下控制病情的患者来说是一个可行的选择。政府和医疗保健系统面临着提供负担得起且可持续的医疗保健服务的压力，特别是在管理慢性病方面。品牌仿製药透过提供具有成本效益的治疗方案，帮助医疗保健系统更有效地管理预算。对治疗慢性疾病的药物的需求为製药公司创造了竞争格局。用于治疗慢性病的品牌药物的专利到期为仿製药製造商以其品牌仿製药进入市场提供了机会。这种竞争可以带来配方、给药方法和包装的创新，从而促进品牌仿製药市场的成长。慢性病影响着全世界的人口，全球品牌仿製药市场的成长与已开发国家和发展中国家对慢性病可及且负担得起的治疗方案的需求相一致。由于生活方式的改变和人口老化，许多慢性病在新兴市场变得越来越普遍。品牌仿製药满足了这些地区对具有成本效益的治疗的需求，推动了市场成长。

主要市场挑战

• 1.监管障碍：仿製药，包括品牌仿製药，必须经过监管审批程序，以确保其安全性、品质和有效性。审批过程中的延迟或复杂性可能会减慢新品牌仿製药产品推向市场的速度。监管机构通常对证明品牌仿製药与其品牌同类药物的生物等效性有严格的要求。满足这些要求可能具有挑战性且耗时，可能会导致市场准入延迟。处理原始品牌药物的专利时可能会出现监管挑战。即使在专利到期后，专利纠纷和法律诉讼也可能会延迟或阻止品牌仿製药的上市。不同国家对仿製药有不同的监管架构和要求。对于希望在全球范围内销售品牌仿製药的製药公司来说，应对这些不同的法规可能会很复杂。确保一致的品质和遵守製造标准对于仿製药的接受至关重要。与品质控制相关的监管障碍可能会影响医疗保健专业人员和患者对品牌仿製药的看法和信任。一些监管体系为创新药物提供资料独占期或市场独占期，这可能会延迟仿製药替代品的进入。这可能会阻碍品牌仿製药的供应，尤其是在独占期较长的市场中。
• 2.不断变化的医疗保健政策：政府经常实施定价法规来控制医疗保健成本并确保病人的负担能力。虽然这些法规可能导致药品价格下降，但它们也会影响仿製药製造商的获利能力，包括那些生产品牌仿製药的製造商。如果定价法规导致利润率极低，製造商可能会不愿意生产或推广品牌仿製药。报销政策决定了保险或政府医疗保健计划可以支付多少药物费用。报销政策的变化，例如品牌仿製药报销率的降低，可能会影响患者对这些产品的取得和需求。医疗保健政策可以影响处方集中特定药物的包含或排除，处方集是保险计划或医疗保健系统涵盖的药物清单。如果品牌仿製药因政策变化而被排除在处方集之外，可能会限制其市场范围和成长潜力。一些医疗保健政策和指南鼓励使用仿製药而不是品牌药以降低成本。虽然这可以使医疗保健系统和患者受益，但它可能会影响品牌仿製药的市场潜力，品牌仿製药被定位为品牌药和仿製药之间的桥樑。与市场独占性相关的智慧财产权法或政策的变化可能会影响品牌仿製药的竞争格局。如果政策延长品牌药物的市场独占期，则可能会延迟仿製药替代品（包括品牌仿製药）的进入。与平行进口（从低成本市场进口和销售品牌仿製药）相关的政策变化可能会影响某些地区品牌仿製药的供应和定价。缺乏清晰度或透明度的医疗保健政策可能会导致患者和医疗保健专业人员感到困惑。这种混乱可能

影响患者和医生对品牌仿製药的接受度，阻碍其市场成长。

主要市场趋势

• 1.数位健康整合的进步：数位健康技术的整合可以透过提供药物提醒、追踪和依从性工具来增强患者的参与度。品牌仿製药价格更实惠，可以从患者参与度的增加中受益，从而改善治疗结果和患者忠诚度。品牌仿製药通常用于管理慢性病，而数位健康解决方案可以远端监控患者的健康状况，这是慢性病管理的重要功能。这种整合可以提高患者对药物治疗方案的依从性，有助于品牌仿製药市场的成长。数位健康平台可以促进远距医疗咨询，医生可以远端诊断和开药，包括品牌仿製药。这可以增加患者获得这些药物的机会，特别是在医疗基础设施有限的地区。数位健康解决方案可以根据患者资料和健康指标制定个人化治疗计划，根据患者个别需求定製品牌仿製药，从而获得更好的治疗结果和患者满意度。数位健康整合还可以提高患者和医疗保健提供者对品牌仿製药的认识。製造商可以使用数位平台向用户宣传品牌仿製药的优势、可用性和成本节约。製药公司可以利用资料分析来深入了解市场趋势、患者偏好和医疗保健利用模式，从而指导品牌仿製药的营销策略和产品定位。
• 2.品牌仿製药领域生物相似药的发展：在某些情况下，生物相似药既与原厂生物药也与品牌仿製药竞争。这种竞争可能会导致价格下降，使患者能够更负担得起治疗，并对品牌仿製药的定价施加压力，从而由于节省成本而增加其采用率。生物相似药可以透过为原本无法负担生物治疗费用的患者提供更实惠的选择来扩大市场，透过提高对具有成本效益的替代品的认识和需求来使品牌仿製药受益。生物相似药可以占据原厂生物製剂和品牌仿製药的部分市场份额，根据竞争格局，可能会影响品牌仿製药市场的成长。生物相似药的引入可以增加围绕生物製剂及其替代品的教育力度，这可以透过创建一个更知情的市场来了解具有成本效益的选择的价值，从而使品牌仿製药受益。为生物相似药制定的监管途径也会影响仿製药（包括品牌仿製药）的监管。随着患者越来越熟悉生物相似药及其益处，他们可能会更愿意考虑替代治疗方案，包括品牌仿製药。患者的偏好和接受度可能会受到生物相似药采用的更广泛背景的影响。

细分市场洞察

药品类别洞察：在药品类别领域，抗高血压类别预计在整个预测期内将大幅市场成长。造成这种增长的因素有很多，包括高血压作为影响数百万人的重大健康问题的全球盛行率。久坐的生活方式和不健康的饮食导致高血压病例持续上升。品牌仿製药提供了一种有效的解决方案，为品牌抗高血压药物提供负担得起的替代品。鑑于高血压是一种慢性疾病，通常需要终生服药，品牌仿製药透过提供具有成本效益的选择来满足持续治疗的需求。北美高昂的医疗费用推动了对品牌药物更实惠的替代品的需求。品牌仿製药为患者和医疗保健系统提供了一种经济高效的选择，有助于他们在该地区的成长。品牌仿製药满足了对可获取药物的需求，特别是针对北美流行的慢性疾病。他们帮助患者管理自己的病情，而无需承担昂贵品牌药物的经济负担。北美健康保险系统的存在，包括私人保险和医疗保险和医疗补助等政府计划，可以透过为这些药物提供保险来鼓励使用更实惠的品牌仿製药。

配销通路洞察：零售药房领域一直是配销通路类别市场的主导力量。零售药局在向患者分发药物（包括品牌仿製药）方面发挥着至关重要的作用。药房货架上的品牌仿製药使寻求负担得起的治疗选择的患者可以轻鬆获得它们。零售药局的药剂师向患者提供有关其药物的信息，包括品牌仿製药。他们可以教育患者了解品牌仿製药的好处、成本节约和有效性，影响他们的看法和接受度。零售药局经常与保险公司和医疗保健系统合作建立处方集，即批准的药物清单。将品牌仿製药纳入这些处方集可以导致处方数量增加和市场成长。零售药局适应患者的财务限制。透过提供品牌仿製药作为更实惠的替代品，药局有助于患者获得药物并坚持用药。在拥有大量零售药房的新兴市场，品牌仿製药对于为大量人群提供负担得起的治疗选择至关重要。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球品牌仿製药市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（烷化剂、抗代谢药、荷尔蒙、抗高血压药、降血脂药、抗忧郁药、抗精神病药、抗癫痫药等）
  • 按应用（肿瘤、心血管疾病、神经系统疾病、急性慢性疼痛、胃肠道疾病、皮肤病、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
  • 按公司划分 (2022)
• 市场地图
  • 按药物类别
  • 按应用
  • 按配销通路
  • 按地区

第 6 章：北美品牌仿製药市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（烷化剂、抗代谢药、荷尔蒙、抗高血压药、降血脂药、抗忧郁药、抗精神病药、抗癫痫药等）
  • 按应用（肿瘤、心血管疾病、神经系统疾病、急性慢性疼痛、胃肠道疾病、皮肤病、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲品牌仿製药市场前景

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（烷化剂、抗代谢药、荷尔蒙、抗高血压药、降血脂药、抗忧郁药、抗精神病药、抗癫痫药等）
  • 按应用（肿瘤、心血管疾病、神经系统疾病、急性慢性疼痛、胃肠道疾病、皮肤病、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区品牌仿製药市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（烷化剂、抗代谢药、荷尔蒙、抗高血压药、降血脂药、抗忧郁药、抗精神病药、抗癫痫药等）
  • 按应用（肿瘤、心血管疾病、神经系统疾病、急性慢性疼痛、胃肠道疾病、皮肤病、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲品牌仿製药市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（烷化剂、抗代谢药、荷尔蒙、抗高血压药、降血脂药、抗忧郁药、抗精神病药、抗癫痫药等）
  • 按应用（肿瘤、心血管疾病、神经系统疾病、急性慢性疼痛、胃肠道疾病、皮肤病、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲品牌仿製药市场前景

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（烷化剂、抗代谢药、荷尔蒙、抗高血压药、降血脂药、抗忧郁药、抗精神病药、抗癫痫药等）
  • 按应用（肿瘤、心血管疾病、神经系统疾病、急性慢性疼痛、胃肠道疾病、皮肤病、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按国家/地区
• MEA：国家分析
  • 南非品牌学名药
  • 沙乌地阿拉伯品牌仿製药
  • 阿联酋品牌仿製药

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球品牌仿製药市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 产品供应
• 最近的发展
• 财务（据报导）
• 主要人员
• SWOT分析
  • Teva Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals Inc.
  • Sanofi-Aventis.
  • Sun Pharmaceutical Industries Inc.
  • Dr Reddy's Laboratories Inc.
  • Endo International PLC.
  • GlaxoSmithKline LLC.
  • Pfizer Inc.
  • Viatris Inc.
  • Apotex Inc.

第 16 章：策略建议

The Global Branded Generics Market achieved a valuation of USD 230.02 Billion in 2022, and it is poised for remarkable growth in the forecast period, with an expected Compound Annual Growth Rate (CAGR) of 6.25% through 2028 and expected to reach USD 333.20 Billion in 2028. Branded generics, which are pharmaceutical drugs re-released under different brand names, have seen increased adoption. These medicines are reintroduced at a lower cost, and while the shape, size, color, and flavor may vary, the medication's core remains the same. This happens when the patent for the drug has expired. Branded generics encompass drugs used to treat various conditions like hypertension, diabetes, back pain, thyroid issues, and arthritis. They offer cost-effective alternatives to stay competitive in the market while maintaining the same level of quality and therapeutic effectiveness.

Key Market Drivers

• 1. Rising Patent Expirations: As the patents of branded drugs expire, generic drug manufacturers gain the legal right to enter the market with their versions. This competition often leads to lower drug prices, making healthcare more affordable for consumers. Moreover, it enables wider access to essential medications, particularly in regions where cost was a barrier, thereby expanding the market. Branded generics are typically priced lower than their branded counterparts, which can yield significant savings for healthcare systems, especially in developing countries or regions with constrained healthcare budgets. Governments and healthcare providers may prefer to prescribe and procure branded generics, further driving market growth. Multiple generic manufacturers entering the market after a patent expiration fosters increased competition. This competition can fuel innovation in terms of formulation, delivery methods, and packaging as manufacturers strive to differentiate their products to gain a larger market share. In some cases, the introduction of numerous generic versions of a drug post-patent expiry can lead to market saturation. Consequently, generic drug prices can significantly decrease due to intense competition, which limits the revenue potential for generic manufacturers but benefits consumers and healthcare systems. The heightened competition in the generic market can incentivize manufacturers to invest in research and development to improve the quality, efficacy, and safety of their generic products. This focus on innovation can further drive the growth of the branded generics market.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 230.02 Billion
Market Size 2028	USD 333.20 Billion
CAGR 2023-2028	6.25%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

• 2. Growing Acceptance by Physicians and Patients: Physician endorsement of branded generics plays a pivotal role in their market growth. When physicians have confidence in the quality and effectiveness of branded generics, they are more inclined to prescribe them to their patients. Physician recommendations and trust in the efficacy of branded generics can alleviate patient concerns about switching from branded drugs to their generic counterparts. Physicians often consider the financial burden on their patients when prescribing medications. If physicians believe that branded generics offer similar therapeutic benefits to branded drugs, they may be more likely to prescribe them to help patients save on healthcare costs. Pharmaceutical companies and healthcare institutions can contribute to educating physicians about the quality, safety, and equivalence of branded generics compared to branded drugs. Proper education can positively influence physicians' acceptance and prescribing habits. Patients may be hesitant about transitioning from well-known branded medications to generic versions. Positive experiences and successful treatment outcomes with branded generics can build patients' confidence in their effectiveness, leading to increased acceptance. Patients often trust their physicians' recommendations. If physicians explain the advantages of branded generics, including their affordability and equivalent therapeutic effects, patients are more likely to accept them. Cost considerations significantly drive patient acceptance. Patients unable to afford expensive branded medications may be more open to using branded generics as long as they are assured of their safety and efficacy.

• 3. Rising Incidence of Chronic Diseases: The increasing global incidence of chronic diseases has generated a growing demand for medications to manage these conditions. Branded generics offer cost-effective alternatives to branded drugs, making them more accessible to a larger population of patients requiring continuous treatment. Chronic diseases often necessitate long-term medication regimens, which can become financially burdensome for patients. Branded generics, being more affordable than their branded counterparts, are a viable option for patients looking to manage their conditions without straining their finances. Governments and healthcare systems face pressure to provide affordable and sustainable healthcare services, especially for managing chronic diseases. Branded generics help healthcare systems manage their budgets more efficiently by offering cost-effective treatment options. The demand for medications to manage chronic diseases creates a competitive landscape for pharmaceutical companies. The expiration of patents for branded drugs used to manage chronic diseases opens up opportunities for generic manufacturers to enter the market with their branded generic versions. This competition can lead to innovation in formulations, delivery methods, and packaging, thereby enhancing the growth of the branded generics market. Chronic diseases affect populations worldwide, and the growth of the global branded generics market aligns with the need for accessible and affordable treatment options for chronic diseases in both developed and developing countries. Many chronic diseases are becoming increasingly prevalent in emerging markets due to lifestyle changes and aging populations. Branded generics address the demand for cost-effective treatments in these regions, driving market growth.

Key Market Challenges

• 1. Regulatory Hurdles: Generic medications, including branded generics, must undergo regulatory approval processes to ensure their safety, quality, and efficacy. Delays or complexities in the approval process can slow down the introduction of new branded generic products to the market. Regulatory authorities often have strict requirements for demonstrating the bioequivalence of branded generics to their branded counterparts. Meeting these requirements can be challenging and time-consuming, potentially causing delays in market entry. Regulatory challenges can arise when dealing with the patents of the original branded drugs. Patent disputes and legal battles can delay or prevent the launch of branded generics even after the patent has expired. Different countries have varying regulatory frameworks and requirements for generic medications. Navigating these diverse regulations can be complex for pharmaceutical companies looking to market branded generics globally. Ensuring consistent quality and adherence to manufacturing standards is crucial for the acceptance of generic medications. Regulatory hurdles related to quality control can affect the perception and trust of healthcare professionals and patients in branded generics. Some regulatory systems offer periods of data exclusivity or market exclusivity for innovator drugs, which can delay the entry of generic alternatives. This can hinder the availability of branded generics, especially in markets with longer exclusivity periods.

• 2. Changing Healthcare Policies: Governments often implement pricing regulations to control healthcare costs and ensure affordability for patients. While these regulations can lead to lower prices for medications, they can also impact the profitability of generic manufacturers, including those producing branded generics. If pricing regulations result in extremely low profit margins, manufacturers might be discouraged from producing or promoting branded generics. Reimbursement policies determine how much of the cost of a medication is covered by insurance or government healthcare programs. Changes in reimbursement policies, such as reduced reimbursement rates for branded generics, can influence patient access and demand for these products. Healthcare policies can influence the inclusion or exclusion of specific medications on formularies, which are lists of drugs covered by insurance plans or healthcare systems. If branded generics are excluded from formularies due to policy changes, it can limit their market reach and growth potential. Some healthcare policies and guidelines encourage the use of generic medications over branded drugs to reduce costs. While this can benefit the healthcare system and patients, it might impact the market potential for branded generics, which are positioned as a bridge between branded and generic drugs. Changes in intellectual property laws or policies related to market exclusivity can affect the competitive landscape for branded generics. If policies extend market exclusivity periods for branded drugs, it can delay the entry of generic alternatives, including branded generics. Changing policies related to parallel imports (importing and selling branded generics from lower-cost markets) can impact the availability and pricing of branded generics in certain regions. Healthcare policies that lack clarity or transparency can lead to confusion among patients and healthcare professionals. This confusion might

affect patient and physician acceptance of branded generics, hindering their market growth.

Key Market Trends

• 1. Advancements in Digital Health Integration: The integration of digital health technologies can enhance patient engagement by offering tools for medication reminders, tracking, and adherence. Branded generics, being more affordable, can benefit from increased patient engagement, leading to improved treatment outcomes and patient loyalty. Branded generics are often used for managing chronic diseases, and digital health solutions enable remote monitoring of patients' health conditions, a valuable feature for chronic disease management. This integration can improve patient compliance with medication regimens, contributing to the growth of the branded generics market. Digital health platforms can facilitate telemedicine consultations, where physicians can remotely diagnose and prescribe medications, including branded generics. This can increase the accessibility of these medications to patients, especially in regions with limited healthcare infrastructure. Digital health solutions can enable personalized treatment plans based on patient data and health metrics, tailoring branded generics to individual patient needs, resulting in better treatment outcomes and patient satisfaction. Digital health integration can also improve awareness of branded generics among patients and healthcare providers. Manufacturers can use digital platforms to educate users about the benefits, availability, and cost savings associated with branded generics. Pharmaceutical companies can employ data analytics to gain insights into market trends, patient preferences, and healthcare utilization patterns, guiding marketing strategies and product positioning for branded generics.

• 2. Development of Biosimilars in the Branded Generics Landscape: Biosimilars compete with both original biologic drugs and branded generics in some cases. This competition can lead to lower prices, making treatment more affordable for patients and putting pressure on the pricing of branded generics, thereby increasing their adoption due to cost savings. Biosimilars can expand the market by providing more affordable options for patients who might have otherwise been unable to afford biologic treatments, benefiting branded generics by raising awareness and demand for cost-effective alternatives. Biosimilars can capture a portion of the market share of both original biologics and branded generics, potentially impacting the growth of the branded generics market depending on the competitive landscape. The introduction of biosimilars can lead to increased education efforts around biologics and their alternatives, which can benefit branded generics by creating a more informed market that understands the value of cost-effective options. Regulatory pathways developed for biosimilars can also impact regulations around generic medications, including branded generics. As patients become more familiar with biosimilars and their benefits, they might become more open to considering alternative treatment options, including branded generics. Patient preferences and acceptance can be influenced by the broader context of biosimilar adoption.

Segmental Insights

Drug Class Insights: Within the Drug Class segment, the Anti-Hypertensive category is expected to witness substantial market growth throughout the forecast period. Several factors contribute to this growth, including the global prevalence of hypertension as a significant health concern affecting millions of individuals. Sedentary lifestyles and unhealthy diets have led to a continuous rise in hypertension cases. Branded generics offer an effective solution by providing affordable alternatives to branded anti-hypertensive drugs. Given that hypertension is a chronic condition often requiring lifelong medication, branded generics address the need for continuous treatment by offering cost-effective options. The high healthcare costs in North America have driven the demand for more affordable alternatives to branded drugs. Branded generics provide a cost-effective option for patients and healthcare systems, contributing to their growth in the region. Branded generics address the need for accessible medications, particularly for chronic diseases that are prevalent in North America. They help patients manage their conditions without the financial burden of expensive branded medications. The presence of health insurance systems in North America, including private insurance and government programs like Medicare and Medicaid, can encourage the use of more affordable branded generics by providing coverage for these medications.

Distribution Channel Insights: The Retail Pharmacy segment has been the dominant force in the market within the Distribution Channel category. Retail pharmacies play a crucial role in distributing medications, including branded generics, to patients. The availability of branded generics on pharmacy shelves makes them readily accessible to patients seeking affordable treatment options. Pharmacists at retail pharmacies provide patients with information about their medications, including branded generics. They can educate patients about the benefits, cost savings, and effectiveness of branded generics, influencing their perception and acceptance. Retail pharmacies often collaborate with insurance companies and healthcare systems to establish formularies, which are lists of approved medications. Including branded generics in these formularies can lead to increased prescriptions and market growth. Retail pharmacies are attuned to patients' financial constraints. By offering branded generics as more affordable alternatives, pharmacies contribute to patient access and adherence to medications. In emerging markets with a significant retail pharmacy presence, branded generics can become essential for providing affordable treatment options to large populations.

Regional Insights: North America, specifically the Branded Generics Market, dominated the market in 2022. North America has seen a significant number of patent expirations for blockbuster drugs, creating opportunities for generic manufacturers to introduce branded generic versions. As a result, the region has experienced substantial growth in the branded generics market as companies capitalize on these opportunities. The high healthcare costs in North America have driven the demand for more affordable alternatives to branded drugs. Branded generics provide a cost-effective option for patients and healthcare systems, contributing to their growth in the region. Branded generics address the need for accessible medications, particularly for chronic diseases that are prevalent in North America. They help patients manage their conditions without the financial burden of expensive branded medications. The presence of health insurance systems in North America, including private insurance and government programs like Medicare and Medicaid, can encourage the use of more affordable branded generics by providing coverage for these medications.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Sanofi-Aventis.
• Sun Pharmaceutical Industries Inc.
• Dr Reddy's Laboratories Inc.
• Endo International PLC.
• GlaxoSmithKline LLC.
• Pfizer Inc.
• Viatris Inc.
• Apotex Inc.

Report Scope:

In this report, the Global Branded Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Branded Generics Market, By Drug Class:

• Alkylating Agents
• Antimetabolites, Hormones
• Anti - Hypertensive
• Lipid Lowering Drugs
• Antidepressants
• Antipsychotics
• Antiepileptics
• Others

Branded Generics Market, By Application:

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Acute & Chronic Pain
• Gastrointestinal Diseases
• Dermatological Diseases
• Others

Branded Generics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Branded Generics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Branded Generics Market.

Available Customizations:

• Global Branded Generics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Branded Generics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 5.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2022)
• 5.3. Market Map
  • 5.3.1 By Drug Class
  • 5.3.2 By Application
  • 5.3.3 By Distribution Channel
  • 5.3.4 By Region

6. North America Branded Generics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 6.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Branded Generics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Branded Generics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Branded Generics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Branded Generics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 7.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 7.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Branded Generics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Branded Generics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Branded Generics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Branded Generics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Branded Generics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Branded Generics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 8.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 8.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Branded Generics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Branded Generics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Branded Generics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Branded Generics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Branded Generics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America Branded Generics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 9.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 9.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Branded Generics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Branded Generics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Branded Generics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Branded Generics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 10.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 10.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Branded Generics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Branded Generics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Branded Generics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Branded Generics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1 Teva Pharmaceutical Industries Ltd.
  • 15.6.2 Lupin Pharmaceuticals Inc.
  • 15.6.3 Sanofi-Aventis.
  • 15.6.4 Sun Pharmaceutical Industries Inc.
  • 15.6.5 Dr Reddy's Laboratories Inc.
  • 15.6.6 Endo International PLC.
  • 15.6.7 GlaxoSmithKline LLC.
  • 15.6.8 Pfizer Inc.
  • 15.6.9 Viatris Inc.
  • 15.6.10 Apotex Inc.

16. Strategic Recommendations